[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fMv5D5j_vHRBFzbqjzY7E6n1iaGh-C4oqvafG6e8La4Q":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":10,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Instituto de Investigacion Sanitaria La Fe",[4],59,false,11,31268,0,41,[13,16,19,22,24,26,28,31],{"name":14,"count":15},"Breast Cancer",4,{"name":17,"count":18},"Surgery",3,{"name":20,"count":21},"Prostate Cancer",2,{"name":23,"count":21},"Palliative Care",{"name":25,"count":21},"Home Care, Hospital-Based",{"name":27,"count":21},"Infertility",{"name":29,"count":30},"AML",1,{"name":32,"count":30},"Epilepsy",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,70,88,115,143,161,186,211,237,255,281,306,331,356,374,401,419,437,463,481,499,524,551,569,594,612,640,658,676,698],{"intervention":43,"totalTrials":30,"cells":44},"G-CSF",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":68},{"trials":46,"activeCount":10},[],{"trials":48,"activeCount":10},[],{"trials":50,"activeCount":10},[],{"trials":52,"activeCount":10},[],{"trials":54,"activeCount":10},[55],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":64,"interventions":66},"NCT03535480","Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure","UNKNOWN",[39],"2020-06","2022-06","2018-06",20,[65],"Premature Ovarian Failure (POF)",[43,67],"ASCOT",{"trials":69,"activeCount":10},[],{"intervention":67,"totalTrials":30,"cells":71},{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":86},{"trials":73,"activeCount":10},[],{"trials":75,"activeCount":10},[],{"trials":77,"activeCount":10},[],{"trials":79,"activeCount":10},[],{"trials":81,"activeCount":10},[82],{"nctId":56,"briefTitle":57,"status":58,"phases":83,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":84,"interventions":85},[39],[65],[43,67],{"trials":87,"activeCount":10},[],{"intervention":89,"totalTrials":30,"cells":90},"Triptorelin acetate",{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":99,"NA":113},{"trials":92,"activeCount":10},[],{"trials":94,"activeCount":10},[],{"trials":96,"activeCount":10},[],{"trials":98,"activeCount":10},[],{"trials":100,"activeCount":10},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT01581359","The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis","COMPLETED",[39],"2015-03","2015-05","2012-03",200,[111,27],"Endometriosis",[89],{"trials":114,"activeCount":10},[],{"intervention":116,"totalTrials":30,"cells":117},"A",{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":141},{"trials":119,"activeCount":10},[],{"trials":121,"activeCount":10},[],{"trials":123,"activeCount":10},[],{"trials":125,"activeCount":10},[],{"trials":127,"activeCount":10},[128],{"nctId":129,"briefTitle":130,"status":131,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":10,"conditions":136,"interventions":139},"NCT03489512","Comparison Trial for Chloraprep Versus Aqueous Chlorhexidine (2%) for the Prevention of Catheter-related Bacteremia","WITHDRAWN",[39],"2020-10-01","2021-04-01","2019-10-01",[137,138],"Sepsis Affecting Skin","Central Venous Catheter Related Bacteremia",[116,140],"B",{"trials":142,"activeCount":10},[],{"intervention":140,"totalTrials":30,"cells":144},{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":153,"NA":159},{"trials":146,"activeCount":10},[],{"trials":148,"activeCount":10},[],{"trials":150,"activeCount":10},[],{"trials":152,"activeCount":10},[],{"trials":154,"activeCount":10},[155],{"nctId":129,"briefTitle":130,"status":131,"phases":156,"primaryCompletion":133,"completion":134,"start":135,"enrollment":10,"conditions":157,"interventions":158},[39],[137,138],[116,140],{"trials":160,"activeCount":10},[],{"intervention":162,"totalTrials":30,"cells":163},"Metformin",{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":182,"NA":184},{"trials":165,"activeCount":10},[],{"trials":167,"activeCount":10},[],{"trials":169,"activeCount":10},[],{"trials":171,"activeCount":10},[172],{"nctId":173,"briefTitle":174,"status":104,"phases":175,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":181},"NCT04826692","TEsting METformin Against Cognitive Decline in HD",[38],"2025-06-10","2022-04-11",60,[180],"Huntington Disease",[162],{"trials":183,"activeCount":10},[],{"trials":185,"activeCount":10},[],{"intervention":187,"totalTrials":30,"cells":188},"Allopurinol",{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":207,"NA":209},{"trials":190,"activeCount":10},[],{"trials":192,"activeCount":10},[],{"trials":194,"activeCount":10},[],{"trials":196,"activeCount":10},[197],{"nctId":198,"briefTitle":199,"status":104,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT01987570","Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.",[38],"2016-07","2012-04",53,[205],"Patients With Grade II Ankle Sprain",[187],{"trials":208,"activeCount":10},[],{"trials":210,"activeCount":10},[],{"intervention":212,"totalTrials":30,"cells":213},"N-acetylcysteine",{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":233,"NA":235},{"trials":215,"activeCount":10},[],{"trials":217,"activeCount":10},[],{"trials":219,"activeCount":10},[],{"trials":221,"activeCount":10},[222],{"nctId":223,"briefTitle":224,"status":104,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"NCT01866644","Effectiveness of N-acetylcysteine on Preservation Solution During Liver Transplantation",[38],"2016-06","2011-09",214,[230],"Unspecified Complication of Liver Transplant",[212,232],"Saline",{"trials":234,"activeCount":10},[],{"trials":236,"activeCount":10},[],{"intervention":232,"totalTrials":30,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":251,"NA":253},{"trials":240,"activeCount":10},[],{"trials":242,"activeCount":10},[],{"trials":244,"activeCount":10},[],{"trials":246,"activeCount":10},[247],{"nctId":223,"briefTitle":224,"status":104,"phases":248,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":249,"interventions":250},[38],[230],[212,232],{"trials":252,"activeCount":10},[],{"trials":254,"activeCount":10},[],{"intervention":256,"totalTrials":30,"cells":257},"Bravelle",{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":277,"NA":279},{"trials":259,"activeCount":10},[],{"trials":261,"activeCount":10},[],{"trials":263,"activeCount":10},[],{"trials":265,"activeCount":10},[266],{"nctId":267,"briefTitle":268,"status":269,"phases":270,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NCT02605070","Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia","TERMINATED",[38],"2017-06-13","2015-11",30,[275],"Male Infertility",[256],{"trials":278,"activeCount":10},[],{"trials":280,"activeCount":10},[],{"intervention":282,"totalTrials":30,"cells":283},"chemotherapy",{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":302,"NA":304},{"trials":285,"activeCount":10},[],{"trials":287,"activeCount":10},[],{"trials":289,"activeCount":10},[],{"trials":291,"activeCount":10},[292],{"nctId":293,"briefTitle":294,"status":104,"phases":295,"primaryCompletion":296,"start":297,"enrollment":298,"conditions":299,"interventions":301},"NCT01728155","European Low and Intermediate Risk Neuroblastoma Protocol",[38],"2022-12-31","2011-01-01",685,[300],"LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES",[282],{"trials":303,"activeCount":10},[],{"trials":305,"activeCount":10},[],{"intervention":307,"totalTrials":30,"cells":308},"Acetylsalicylic acid",{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":327,"NA":329},{"trials":310,"activeCount":10},[],{"trials":312,"activeCount":10},[],{"trials":314,"activeCount":10},[],{"trials":316,"activeCount":10},[317],{"nctId":318,"briefTitle":319,"status":269,"phases":320,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":326},"NCT02174328","Prevention of Preeclampsia With Aspirin in Recipients of Donated Oocytes.",[38],"2018-04-20","2014-05-21",81,[325],"Pre-Eclampsia",[307],{"trials":328,"activeCount":10},[],{"trials":330,"activeCount":10},[],{"intervention":332,"totalTrials":30,"cells":333},"progesterone 200 mg \u002F day vaginally",{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":338,"PHASE3":340,"PHASE4":352,"NA":354},{"trials":335,"activeCount":10},[],{"trials":337,"activeCount":10},[],{"trials":339,"activeCount":10},[],{"trials":341,"activeCount":10},[342],{"nctId":343,"briefTitle":344,"status":131,"phases":345,"primaryCompletion":346,"completion":346,"start":347,"enrollment":10,"conditions":348,"interventions":350},"NCT01796522","Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery",[38],"2013-05","2013-03",[349],"Preterm Delivery.",[332,351],"nifedipine",{"trials":353,"activeCount":10},[],{"trials":355,"activeCount":10},[],{"intervention":351,"totalTrials":30,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":370,"NA":372},{"trials":359,"activeCount":10},[],{"trials":361,"activeCount":10},[],{"trials":363,"activeCount":10},[],{"trials":365,"activeCount":10},[366],{"nctId":343,"briefTitle":344,"status":131,"phases":367,"primaryCompletion":346,"completion":346,"start":347,"enrollment":10,"conditions":368,"interventions":369},[38],[349],[332,351],{"trials":371,"activeCount":10},[],{"trials":373,"activeCount":10},[],{"intervention":375,"totalTrials":30,"cells":376},"GROUP 1: Long testosterone",{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":397,"NA":399},{"trials":378,"activeCount":10},[],{"trials":380,"activeCount":10},[],{"trials":382,"activeCount":10},[],{"trials":384,"activeCount":10},[385],{"nctId":386,"briefTitle":387,"status":104,"phases":388,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":394},"NCT03378713","Clinical Trial to Assess the Effect of Testosterone in Patients With Poor Ovarian Response (TESTOPRIM)",[38],"2019-02-11","2017-08-07",63,[393],"Infertility, Female",[375,395,396],"GROUP 2: Short testosterone","GROUP 3: Control",{"trials":398,"activeCount":10},[],{"trials":400,"activeCount":10},[],{"intervention":395,"totalTrials":30,"cells":402},{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":415,"NA":417},{"trials":404,"activeCount":10},[],{"trials":406,"activeCount":10},[],{"trials":408,"activeCount":10},[],{"trials":410,"activeCount":10},[411],{"nctId":386,"briefTitle":387,"status":104,"phases":412,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":413,"interventions":414},[38],[393],[375,395,396],{"trials":416,"activeCount":10},[],{"trials":418,"activeCount":10},[],{"intervention":396,"totalTrials":30,"cells":420},{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":433,"NA":435},{"trials":422,"activeCount":10},[],{"trials":424,"activeCount":10},[],{"trials":426,"activeCount":10},[],{"trials":428,"activeCount":10},[429],{"nctId":386,"briefTitle":387,"status":104,"phases":430,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":431,"interventions":432},[38],[393],[375,395,396],{"trials":434,"activeCount":10},[],{"trials":436,"activeCount":10},[],{"intervention":438,"totalTrials":30,"cells":439},"Ganirelix 0.25 mg.",{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":459,"NA":461},{"trials":441,"activeCount":10},[],{"trials":443,"activeCount":10},[],{"trials":445,"activeCount":10},[],{"trials":447,"activeCount":10},[448],{"nctId":449,"briefTitle":450,"status":104,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":456},"NCT02118051","Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.",[38],"2017-06","2013-09",234,[27],[438,457,458],"Recombinant choriogonadotropin alfa","Micronized natural progesterone.",{"trials":460,"activeCount":10},[],{"trials":462,"activeCount":10},[],{"intervention":457,"totalTrials":30,"cells":464},{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":477,"NA":479},{"trials":466,"activeCount":10},[],{"trials":468,"activeCount":10},[],{"trials":470,"activeCount":10},[],{"trials":472,"activeCount":10},[473],{"nctId":449,"briefTitle":450,"status":104,"phases":474,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":475,"interventions":476},[38],[27],[438,457,458],{"trials":478,"activeCount":10},[],{"trials":480,"activeCount":10},[],{"intervention":458,"totalTrials":30,"cells":482},{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":495,"NA":497},{"trials":484,"activeCount":10},[],{"trials":486,"activeCount":10},[],{"trials":488,"activeCount":10},[],{"trials":490,"activeCount":10},[491],{"nctId":449,"briefTitle":450,"status":104,"phases":492,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":493,"interventions":494},[38],[27],[438,457,458],{"trials":496,"activeCount":10},[],{"trials":498,"activeCount":10},[],{"intervention":500,"totalTrials":30,"cells":501},"Apixaban 2.5 MG",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":518,"PHASE4":520,"NA":522},{"trials":503,"activeCount":10},[],{"trials":505,"activeCount":10},[],{"trials":507,"activeCount":10},[508],{"nctId":509,"briefTitle":510,"status":269,"phases":511,"primaryCompletion":512,"completion":513,"start":514,"enrollment":178,"conditions":515,"interventions":517},"NCT04106700","Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs",[37],"2020-08-26","2020-10-05","2019-04-12",[516],"Venous Thromboembolism",[500],{"trials":519,"activeCount":10},[],{"trials":521,"activeCount":10},[],{"trials":523,"activeCount":10},[],{"intervention":525,"totalTrials":30,"cells":526},"Decapeptyl® diario",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":545,"PHASE4":547,"NA":549},{"trials":528,"activeCount":10},[],{"trials":530,"activeCount":10},[],{"trials":532,"activeCount":10},[533],{"nctId":534,"briefTitle":535,"status":104,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":543},"NCT02244151","Evaluation of Time Interval Between Ovulation Trigger With Triptorelin Acetate and Oocyte Retrieval",[37],"2018-02-01","2018-02-02","2014-09",130,[542],"Female Urogenital Diseases",[525,544],"Decapeptyl® daily",{"trials":546,"activeCount":10},[],{"trials":548,"activeCount":10},[],{"trials":550,"activeCount":10},[],{"intervention":544,"totalTrials":30,"cells":552},{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":563,"PHASE4":565,"NA":567},{"trials":554,"activeCount":10},[],{"trials":556,"activeCount":10},[],{"trials":558,"activeCount":10},[559],{"nctId":534,"briefTitle":535,"status":104,"phases":560,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":561,"interventions":562},[37],[542],[525,544],{"trials":564,"activeCount":10},[],{"trials":566,"activeCount":10},[],{"trials":568,"activeCount":10},[],{"intervention":570,"totalTrials":30,"cells":571},"Injection of autologous fatty tissue associated with autologous platelet-rich plasma.",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":573,"activeCount":10},[],{"trials":575,"activeCount":10},[],{"trials":577,"activeCount":10},[578],{"nctId":579,"briefTitle":580,"status":104,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":63,"conditions":584,"interventions":586},"NCT03961126","Evaluation of Vulvar Lichen Sclerosus Treatment Using Adipose Tissue Associated With Autologous Platelet-rich Plasma.",[37],"2019-12-12","2017-09-06",[585],"Vulvar Lichen Sclerosus",[570,587],"Corticosteroids",{"trials":589,"activeCount":10},[],{"trials":591,"activeCount":10},[],{"trials":593,"activeCount":10},[],{"intervention":587,"totalTrials":30,"cells":595},{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":597,"activeCount":10},[],{"trials":599,"activeCount":10},[],{"trials":601,"activeCount":10},[602],{"nctId":579,"briefTitle":580,"status":104,"phases":603,"primaryCompletion":582,"completion":582,"start":583,"enrollment":63,"conditions":604,"interventions":605},[37],[585],[570,587],{"trials":607,"activeCount":10},[],{"trials":609,"activeCount":10},[],{"trials":611,"activeCount":10},[],{"intervention":613,"totalTrials":30,"cells":614},"Testosterone",{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":616,"activeCount":10},[],{"trials":618,"activeCount":10},[],{"trials":620,"activeCount":10},[621],{"nctId":622,"briefTitle":623,"status":104,"phases":624,"primaryCompletion":625,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":631},"NCT01310647","Antral Follicle Priming Prior to ICSI (Intracytoplasmic Sperm Injection) in Previously Diagnosed Low Responders",[37],"2012-12","2014-02","2011-06",66,[630],"Ovarian Diseases",[613,632,633],"Estradiol","CombEq",{"trials":635,"activeCount":10},[],{"trials":637,"activeCount":10},[],{"trials":639,"activeCount":10},[],{"intervention":632,"totalTrials":30,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":652,"PHASE4":654,"NA":656},{"trials":643,"activeCount":10},[],{"trials":645,"activeCount":10},[],{"trials":647,"activeCount":10},[648],{"nctId":622,"briefTitle":623,"status":104,"phases":649,"primaryCompletion":625,"completion":626,"start":627,"enrollment":628,"conditions":650,"interventions":651},[37],[630],[613,632,633],{"trials":653,"activeCount":10},[],{"trials":655,"activeCount":10},[],{"trials":657,"activeCount":10},[],{"intervention":633,"totalTrials":30,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":661,"activeCount":10},[],{"trials":663,"activeCount":10},[],{"trials":665,"activeCount":10},[666],{"nctId":622,"briefTitle":623,"status":104,"phases":667,"primaryCompletion":625,"completion":626,"start":627,"enrollment":628,"conditions":668,"interventions":669},[37],[630],[613,632,633],{"trials":671,"activeCount":10},[],{"trials":673,"activeCount":10},[],{"trials":675,"activeCount":10},[],{"intervention":677,"totalTrials":30,"cells":678},"lacosamide",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":687,"NA":689},{"trials":680,"activeCount":10},[],{"trials":682,"activeCount":10},[],{"trials":684,"activeCount":10},[],{"trials":686,"activeCount":10},[],{"trials":688,"activeCount":10},[],{"trials":690,"activeCount":10},[691],{"nctId":692,"briefTitle":693,"status":104,"phases":694,"primaryCompletion":625,"completion":625,"start":202,"enrollment":695,"conditions":696,"interventions":697},"NCT01858870","Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication",[],860,[32],[677],{"intervention":699,"totalTrials":30,"cells":700},"Azithromycin",{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":707,"PHASE4":709,"NA":711},{"trials":702,"activeCount":10},[],{"trials":704,"activeCount":10},[],{"trials":706,"activeCount":10},[],{"trials":708,"activeCount":10},[],{"trials":710,"activeCount":10},[],{"trials":712,"activeCount":10},[713],{"nctId":714,"briefTitle":715,"status":104,"phases":716,"primaryCompletion":717,"completion":718,"start":719,"enrollment":273,"conditions":720,"interventions":722},"NCT01463371","Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis",[40],"2007-04","2007-09","2006-10",[721],"Bronchiectasis",[699]]